In addition to our previous success in establishing patient-derived CIC-DUX4 sarcoma cells and confirming the retention of the CIC-DUX4 fusion gene [10], we have significantly expanded the opportunity to use CAMs for the characterization of patient-derived cancer samples. This evidence concerns the gene DUX4 and sarcoma.